8,182 companies
Ares Energy Infrastructure V ASP Fund, a series of Alternative Strategies Private Equity Platform, LLC
North Carolina
Inactive
Areteia Therapeutics, Inc.
North Carolina
Argolyn Bioscience Inc
North Carolina
Inactive
Argomed Inc
North Carolina
Inactive
ARGS
Argos Therapeutics Inc
The ADAPT trial is a randomized, multicenter, open label trial comparing combination therapy with rocapuldencel-T and sunitinib (or another targeted therapy) to monotherapy with sunitinib (or another targeted therapy) for the treatment of newly diagnosed metastatic renal cell carcinoma (mRCC). A total of 462 previously untreated patients were enrolled in the ADAPT trial and randomized 2:1 between combination treatment with rocapuldencel-T and sunitinib (combination arm) vs.
North Carolina
Inactive
NASDAQ
Argyle Company, Inc.
North Carolina
Inactive
Aries USA, Inc.
North Carolina
Arjuna Capital
North Carolina
Arlington Chattanooga Apartments, LLC
North Carolina
Inactive
Armor Defense Systems Inc.
North Carolina
Inactive
Armor Investment Advisors, LLC
North Carolina
Armor Technologies LLC
North Carolina
Inactive
Arngar Inc
North Carolina
Inactive
Arosa Acquisitions Investors, LLC
North Carolina
Inactive
Arpio, Inc.
North Carolina
Arrayex Inc
North Carolina
Inactive
Arrevus, Inc.
North Carolina
Inactive
Arrington Aleworks, LLC
North Carolina
Inactive
Arrivo BioVentures, LLC
North Carolina
Arsenal Digital Solutions Worldwide Inc
North Carolina
Inactive